Martha (Muffy) Carter

Chief Regulatory Officer

Martha (Muffy) Carter joined Albireo in November 2016. Muffy has four decades of regulatory experience in the biopharmaceutical industry. Most recently, Muffy was Chief Regulatory Officer and Senior Vice President of Aegerion Pharmaceuticals, a biopharmaceutical company focused in rare diseases, where she established global regulatory and quality functions and played a key role in bringing JUXTAPID®/LOJUXTA® (lomitapide) for the treatment of homozygous familial hypercholesterolemia to market in 36 countries. Prior to Aegerion, she served as Senior Vice President and Chief Regulatory Officer at Proteon Therapeutics and Senior Vice President, Regulatory Affairs at Trine Pharmaceuticals. Earlier in her career, Muffy held various positions of increasing responsibility in regulatory affairs, strategic planning and compliance. She has authored or co-authored numerous publications on regulatory matters and professional ethics. Muffy holds a B.A. in biology from Northeastern University.

Team members

Ron Cooper

President and Chief Executive Officer

Martha (Muffy) Carter

Chief Regulatory Officer

Jason Duncan

General Counsel

Per-Göran Gillberg, Ph.D., Prof.

Vice President, Development and Co-Founder

Jan Mattsson, Ph.D.

Chief Operating Officer and Co-Founder

Simon Harford

Chief Financial Officer

Patrick Horn, M.D., Ph.D.

Chief Medical Officer

Kristina Torfgård, Ph.D.

Vice President, Global Project Head